Monday, 26 Aug 2019

You are here

Infliximab Does Not Increase Perioperative Infection

Staying on a TNF inhibitor (TNFi) throughout major surgery has generatlly been associated with higher rates of perioperative infection (https://buff.ly/2iBFVjp).  On the other hand, discontinuation of the TNFi prior to surgery is associated with lower rates of  infection (https://buff.ly/2iAFZQf)

George and colleagues analyzed the timing of inflixiamb discontinuation before elective arthroplasty and found that infliximab given within 4 weeks of elective knee or hip arthroplasty was not associated with a higher risk of short  or long-term serious infection. 

Infection risk was primarily associated with glucocorticoid use, especially >10 mg/day. The 30-day infection risk was double for short term infection (OR 2.11; 95% CI 1.30–3.40) and long term prosthetic infections (HR 2.70; 95% CI 1.30–5.60). Other risk factors for infection included elderly age, comorbidities, revision surgery, and previous hospitalized infection.

They examined infliximab patients hospitalized for infection (within 30 days) and found an event rate of 6.3% (270 out of 4,288 surgeries) They then compared infliximab use - those stopping infliximab <4 weeks of surgery and compared this cohort to those stopping infliximab versus longer 8–12 weeks.  The overall infection rate did not differ between groups and the long term prosthetic infection rates were also similar between group (2.9 per 100 person-years).

 

 

Add new comment

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.